Document is current
Any future updates will be listed below
-
Authors
Wang, Yanling
Xue, Shengbai
Xu, Haiyan
Ma, Jingyu
Wu, Siming
Guo, Keying
Fang, Yaqun
Cui, Jiujie
Wang, Liwei https://orcid.org/0000-0002-4122-4444
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82373133)
National Natural Science Foundation of China (82272906)
National Natural Science Foundation of China (82103087)
National Natural Science Foundation of China (82171824)
Science and Technology Commission of Shanghai Municipality (25ZR1402469)
Science and Technology Commission of Shanghai Municipality (25SF1900600)
Project from CSCO Clinical Oncology Research Foundation (Y-2019AZZD‐0513)
Shanghai Municipal Education Commission - Gao Feng Clinical Medicine Grant Support (20161312)
Shanghai Leading Talents Project, and the Innovative Research Team of High‐Level Local Universities in Shanghai (SHSMU‐ZDCX20210802)
- License Information
-
More Information
Article History
Received: 21 January 2026
Revised: 26 March 2026
Accepted: 8 April 2026
First Online: 25 April 2026
Declarations
:
: Clinical data collection was approved by the Ethics Committee of Renji Hospital, Shanghai Jiao Tong University School of Medicine (Ethics Approval No.: RA-2025–839). The study complied with the Declaration of Helsinki. Fresh pancreatic ductal adenocarcinoma tissue for PDX was obtained from patients who underwent surgical resection at Shanghai Renji Hospital with approval by the Ethics Committee of Renji Hospital, affiliated to Shanghai Jiao Tong University School of Medicine (Shanghai, China, KY [2019]035). All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Renji Hospital, Shanghai Jiao Tong University School of Medicine (Ethics Approval No.: RA-2025–377). The study were conducted in accordance with the National Guidelines for Laboratory Animal Welfare (GB/T 35892–2018, China).
: The authors declare no potential conflicts of interest.
